What is ORMP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.17B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ORMP?

P/E (TTM) is 0.98 and 52-week range is $2.09 to $5.47 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ORMP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ORMP?

The company profile lists revenue (TTM) near $2M, net income (TTM) near -$1.76B, EPS (TTM) near $4.13 when available from the market-data feed. Figures are informational and may lag live markets.

Does ORMP show a dividend on Chartloom?

The overview lists ex-dividend date Jan 16, 2026 when those figures are present. Dividend history is compiled from vendor data, not a distribution notice.

Where is Oramed Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 41.6M shares outstanding, ISIN US68403P2039 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Oramed Pharmaceuticals Inc

$ORMP

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.

Employees

Website

oramed.com/

IPO

2002-04-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US68403P2039

Headquarters

New York City, New York, US

Shares outstanding

41.6M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

45.10%

Browse other companiesFree AI scores and summaries for more stocks